الانتقال الى المحتويات

داء الخلايا المِنْجلية لدى الأطفال

معالجة فقر الدم

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (يفتح نافذة جديدة)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Source‎: Lancet Haematol. 2023 ;10(4):e261-71.

مفهرسة‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (يفتح نافذة جديدة)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (يفتح نافذة جديدة)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Source‎: Acta Haematol 1995;94(3):128-34.

مفهرسة‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (يفتح نافذة جديدة)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (يفتح نافذة جديدة)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Source‎: Haematologica 2006;91(8):1076-83.

مفهرسة‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (يفتح نافذة جديدة)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (يفتح نافذة جديدة)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Source‎: J Obstet Gynaecol 2007;27(1):82-3.

مفهرسة‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (يفتح نافذة جديدة)